According to preliminary data, approximately 27% of breast cancer patients have PIK3CA mutation, more than 20% of endometrial cancer patients have PIK3CA mutation, and approximately 14% of colon cancer patients have PIK3CA mutation [41–44]. This evidence concerns the gene PIK3CA and breast carcinoma.